British Biotechnology losses increase to 13m pounds
Your support helps us to tell the story
From reproductive rights to climate change to Big Tech, The Independent is on the ground when the story is developing. Whether it's investigating the financials of Elon Musk's pro-Trump PAC or producing our latest documentary, 'The A Word', which shines a light on the American women fighting for reproductive rights, we know how important it is to parse out the facts from the messaging.
At such a critical moment in US history, we need reporters on the ground. Your donation allows us to keep sending journalists to speak to both sides of the story.
The Independent is trusted by Americans across the entire political spectrum. And unlike many other quality news outlets, we choose not to lock Americans out of our reporting and analysis with paywalls. We believe quality journalism should be available to everyone, paid for by those who can afford it.
Your support makes all the difference.LOSSES at British Biotechnology, the pharmaceutical research and development company deepened from pounds 11.6m to pounds 13.1m as the company increased spending on clinical trials.
However, spending on the research of new drugs in the 12 months to 30 April was maintained at the previous year's levels.
Losses of this nature are par for the course for such companies. James Noble, finance director, said losses would continue for at least three years before the investment on research showed the expected returns.
Biotechnology is developing drugs to fight Aids, asthma and cancer, all of which are in clinical trials. This means the company has the added costs of paying hospitals to test the drugs.
Operating losses were pounds 17.7m, compared with pounds 15.2m. Biotechnology was helped by interest on cash balances of pounds 50m. Interest received was pounds 4.8m in 1993, up from pounds 3.9m. The company's balance sheet was bolstered by pounds 30m raised when Biotechnology was floated on the stock market last July.
The company also sold its medical equipment business yesterday. British Biotechnology Products, mainly a distribution operation, was acquired by Techne, a US company, for dollars 5m ( pounds 3.2m). BBP was the sole source of revenue for the group, but Mr Noble said the division needed capital investment and the company did want to spend money on a non-core activity.
Join our commenting forum
Join thought-provoking conversations, follow other Independent readers and see their replies
Comments